Lifesci Capital Has Bullish Estimate for CRNX Q2 Earnings

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) – Lifesci Capital boosted their Q2 2026 earnings per share (EPS) estimates for Crinetics Pharmaceuticals in a research note issued on Friday, May 8th. Lifesci Capital analyst K. Dellorusso now forecasts that the company will post earnings of ($1.22) per share for the quarter, up from their prior estimate of ($1.34). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Crinetics Pharmaceuticals’ current full-year earnings is ($4.95) per share. Lifesci Capital also issued estimates for Crinetics Pharmaceuticals’ Q3 2026 earnings at ($1.18) EPS, Q4 2026 earnings at ($1.10) EPS and FY2026 earnings at ($4.73) EPS.

CRNX has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a research report on Monday, April 20th. The Goldman Sachs Group raised Crinetics Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $67.00 price objective for the company in a research report on Monday, January 12th. Oppenheimer lowered their price objective on Crinetics Pharmaceuticals from $87.00 to $84.00 and set an “outperform” rating for the company in a research report on Monday. Wall Street Zen downgraded Crinetics Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, Citizens Jmp lowered their price objective on Crinetics Pharmaceuticals from $97.00 to $95.00 and set a “market outperform” rating for the company in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $76.13.

Crinetics Pharmaceuticals Stock Performance

Shares of Crinetics Pharmaceuticals stock opened at $36.55 on Tuesday. Crinetics Pharmaceuticals has a one year low of $25.83 and a one year high of $57.99. The company has a market cap of $3.85 billion, a PE ratio of -7.12 and a beta of 0.28. The business has a 50-day simple moving average of $38.14 and a 200-day simple moving average of $43.81.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.23) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.01). Crinetics Pharmaceuticals had a negative return on equity of 43.96% and a negative net margin of 2,747.18%.The company had revenue of $10.73 million for the quarter, compared to analyst estimates of $8.51 million. During the same period in the prior year, the firm posted ($1.04) earnings per share. The business’s quarterly revenue was up 2873.4% compared to the same quarter last year.

Insider Transactions at Crinetics Pharmaceuticals

In related news, Director Coelho Rogerio Vivaldi sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $36.15, for a total value of $180,750.00. Following the completion of the transaction, the director directly owned 16,300 shares of the company’s stock, valued at $589,245. This represents a 23.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Stephen F. Betz sold 10,612 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $37.37, for a total value of $396,570.44. Following the completion of the transaction, the insider directly owned 137,101 shares of the company’s stock, valued at $5,123,464.37. This trade represents a 7.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 142,380 shares of company stock valued at $5,569,475 over the last three months. 3.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Crinetics Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Crinetics Pharmaceuticals by 11.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,311 shares of the company’s stock valued at $1,995,000 after buying an additional 6,148 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Crinetics Pharmaceuticals by 6.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,581 shares of the company’s stock valued at $11,658,000 after buying an additional 22,305 shares during the last quarter. Strs Ohio purchased a new stake in Crinetics Pharmaceuticals in the first quarter valued at approximately $124,000. Invesco Ltd. lifted its stake in Crinetics Pharmaceuticals by 11.7% in the second quarter. Invesco Ltd. now owns 78,140 shares of the company’s stock valued at $2,247,000 after buying an additional 8,181 shares during the last quarter. Finally, Sei Investments Co. lifted its stake in Crinetics Pharmaceuticals by 20.6% in the second quarter. Sei Investments Co. now owns 60,180 shares of the company’s stock valued at $1,731,000 after buying an additional 10,269 shares during the last quarter. 98.51% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Crinetics Pharmaceuticals

Here are the key news stories impacting Crinetics Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital raised its Q2, Q3, and Q4 2026 EPS estimates for Crinetics Pharmaceuticals and kept a Strong-Buy rating, signaling improved near-term expectations. The firm also lifted its FY2026 EPS estimate from a larger loss to a somewhat smaller loss.
• Positive Sentiment: A Yahoo Finance-linked note said analysts are lifting estimates after Crinetics reported first-quarter earnings, suggesting the recent quarter may have reassured some investors about the company’s execution. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
• Neutral Sentiment: Oppenheimer cut its price target on Crinetics Pharmaceuticals to $84 from $87, but maintained an Outperform rating. This is still above the current trading level, yet the cut can weigh on sentiment. Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Cut to $84.00 by Analysts at Oppenheimer
• Neutral Sentiment: HC Wainwright trimmed multiple longer-term EPS estimates, including FY2026, FY2027, FY2028, and FY2029, reflecting a more conservative outlook beyond the next few quarters.
• Neutral Sentiment: Crinetics remains a loss-making biotech, with consensus FY2026 EPS still expected at a loss of $4.95 per share, so the stock is highly sensitive to changes in development and profitability expectations.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.